Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19
© 2021 International Society of Nephrology. Published by Elsevier Inc..
INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients.
METHODS: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed.
RESULTS: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug.
CONCLUSION: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Kidney international reports - 6(2021), 9 vom: 30. Sept., Seite 2305-2315 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Acute kidney injury |
|---|
| Anmerkungen: |
Date Revised 26.04.2022 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.ekir.2021.06.023 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM327961392 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM327961392 | ||
| 003 | DE-627 | ||
| 005 | 20231225201938.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ekir.2021.06.023 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1093.xml |
| 035 | |a (DE-627)NLM327961392 | ||
| 035 | |a (NLM)34250317 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Buxeda, Anna |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Use and Safety of Remdesivir in Kidney Transplant Recipients With COVID-19 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2021 International Society of Nephrology. Published by Elsevier Inc. | ||
| 520 | |a INTRODUCTION: Remdesivir has demonstrated antiviral activity against coronavirus, shortening the time to recovery in adults hospitalized with moderate/severe COVID-19. Severe adverse events such as acute kidney injury have been reported. Scant data are available on the use and safety of remdesivir in kidney transplant recipients | ||
| 520 | |a METHODS: We present a multicenter cohort study of 51 kidney transplant recipients with COVID-19 treated with remdesivir. Outcomes and safety were assessed | ||
| 520 | |a RESULTS: Mean age at diagnosis was 60 years, with a median time since kidney transplant of 4.5 years. Mean time since admission to remdesivir was 2 days. Twenty-eight patients (54.9%) required mechanical ventilation (19 noninvasive). Mortality was 18.9% and markedly higher if aged ≥65 years (45% vs. 3.2% in younger patients). Acute kidney injury was present in 27.7% of patients, but was diagnosed in 50% before treatment. No patients required remdesivir discontinuation because of adverse events. We did not find significant hepatoxicity or systemic symptoms resulting from the drug | ||
| 520 | |a CONCLUSION: In our cohort of kidney transplant recipients, remdesivir was well tolerated and safe in renal and hepatic toxicity, but randomized trials are needed to assess its efficacy | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV2l | |
| 650 | 4 | |a acute kidney injury | |
| 650 | 4 | |a immunosuppression | |
| 650 | 4 | |a kidney transplantation | |
| 650 | 4 | |a remdesivir | |
| 700 | 1 | |a Arias-Cabrales, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Pérez-Sáez, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Cacho, Judit |e verfasserin |4 aut | |
| 700 | 1 | |a Cabello Pelegrin, Sheila |e verfasserin |4 aut | |
| 700 | 1 | |a Melilli, Edoardo |e verfasserin |4 aut | |
| 700 | 1 | |a Aladrén, María José |e verfasserin |4 aut | |
| 700 | 1 | |a Galeano, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Lorenzo, Inmaculada |e verfasserin |4 aut | |
| 700 | 1 | |a Mazuecos, Auxiliadora |e verfasserin |4 aut | |
| 700 | 1 | |a Saura, Isabel María |e verfasserin |4 aut | |
| 700 | 1 | |a Franco, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Ruiz-Fuentes, María Del Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Cámara, Luis Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Siverio, Orlando |e verfasserin |4 aut | |
| 700 | 1 | |a Martin, María Luisa |e verfasserin |4 aut | |
| 700 | 1 | |a González-García, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a López, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Martin-Moreno, Paloma Leticia |e verfasserin |4 aut | |
| 700 | 1 | |a Moina, Iñigo |e verfasserin |4 aut | |
| 700 | 1 | |a Moral Berrio, Esperanza |e verfasserin |4 aut | |
| 700 | 1 | |a Moreso, Francesc |e verfasserin |4 aut | |
| 700 | 1 | |a Portolés, José María |e verfasserin |4 aut | |
| 700 | 1 | |a Santana-Estupiñán, Raquel |e verfasserin |4 aut | |
| 700 | 1 | |a Zárraga, Sofía |e verfasserin |4 aut | |
| 700 | 1 | |a Canal, Cristina |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez-Álvarez, Emilio |e verfasserin |4 aut | |
| 700 | 1 | |a Pascual, Julio |e verfasserin |4 aut | |
| 700 | 1 | |a Crespo, Marta |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Kidney international reports |d 2016 |g 6(2021), 9 vom: 30. Sept., Seite 2305-2315 |w (DE-627)NLM264185072 |x 2468-0249 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2021 |g number:9 |g day:30 |g month:09 |g pages:2305-2315 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ekir.2021.06.023 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2021 |e 9 |b 30 |c 09 |h 2305-2315 | ||